Use of modified phage for capturing and subtyping of cancer cells

Abstract

The present disclosure relates to genetically engineered phage that bind to cancer cells. The genetically engineered phage can be used to isolate cancer cells, for example, circulating cancer cells, by binding to antigens specifically expressed on the surface of cancer cells. Thus, the present disclosure provides compositions, methods, and kits for improved cancer diagnosis that are useful for improved cancer treatment.

Dependencies are inferred from the claim text.